title: Extensive intestinal first-pass elimination and predominant hepatic distribution of berberine explain its low plasma levels in rats.
abstract: Berberine, one of the most commonly used natural products, exhibits a poor plasma concentration-effect relationship whose underlying mechanisms remain largely unclear. This study was designed to test the hypothesis that extensive first-pass elimination and abundant tissue distribution of berberine may be its specific pharmacokinetic properties. For that, four different dosing routes, intragastric, intraduodenal, intraportal, and intravenous, were used to investigate the gastric, intestinal, and hepatic first-pass elimination of berberine. After intragastric dosing, approximately half of berberine ran intact through the gastrointestinal tract and another half was disposed of by the small intestine, leading to an extremely low extent of absolute oral bioavailability in rats (0.36%). Moreover, the major berberine metabolites were identified and quantified in rat enterocyte S9 fractions, portal vein plasma, and intestinal perfusates; plasma concentrations and tissue distribution of berberine and its major metabolites were determined as well. Data indicated that M1, M2 glucuronide, and M3 were the major metabolites generated from the small intestine and that there was a 70-fold increase in the ratio of the area under the concentration-time curve value for berberine (liver versus plasma). We conclude that intestinal first-pass elimination of berberine is the major barrier of its oral bioavailability and that its high extraction and distribution in the liver could be other important factors that lead to its low plasma levels in rats.
authors.affiliation: China Pharmaceutical University, Nanjing, Jiangsu, China.
authors.forename: Yi-Tong
authors.initials: YT
authors.lastname: Liu
authors.forename: Hai-Ping
authors.initials: HP
authors.lastname: Hao
authors.forename: Hong-Guang
authors.initials: HG
authors.lastname: Xie
authors.forename: Li
authors.initials: L
authors.lastname: Lai
authors.forename: Qiong
authors.initials: Q
authors.lastname: Wang
authors.forename: Chang-Xiao
authors.initials: CX
authors.lastname: Liu
authors.forename: Guang-Ji
authors.initials: GJ
authors.lastname: Wang
mesh_terms: D000284:Administration, Oral; D000818:Animals; D019540:Area Under Curve; D001599:Berberine / Q000008:administration & dosage / Q000097:blood / Q000493:pharmacokinetics; D002853:Chromatography, Liquid; D020895:Enterocytes / Q000166:cytology / Q000378:metabolism; D066298:In Vitro Techniques; D007275:Injections, Intravenous; D007421:Intestine, Small / Q000166:cytology / Q000378:metabolism*; D008099:Liver / Q000378:metabolism*; D008297:Male; D050216:Metabolic Detoxication, Phase I; D010477:Perfusion; D051381:Rats; D017207:Rats, Sprague-Dawley; D013347:Subcellular Fractions / Q000378:metabolism; D053719:Tandem Mass Spectrometry; D014018:Tissue Distribution
chemical_list: D001599:Berberine